Glenmark inks deal with SaNOtize to commercialize COVID-19 treatment spray in Asia

INDIA – Glenmark Pharmaceuticals has signed an agreement with Canadia’s biotech firm SaNOtize Research and Development Group to commercialize its Nitric Oxide Nasal spray (NONS) for Covid-19 treatment in India and other Asian markets. Glenmark will collaborate with SaNOtize to manufacture, market and distribute this breakthrough Nitric Oxide Nasal Spray through their exclusive long-term partnership. It expects to launch the nasal spray this year under the brand name ‘FabiSpray’ in India. ”The Phase III clinical trial for NONS is expected to be completed, followed by commercial launch under the brand…

Read More